Literature DB >> 15606506

Guidelines for prescribing azathioprine in dermatology.

A V Anstey1, S Wakelin, N J Reynolds.   

Abstract

Azathioprine has been available as an immunosuppressive agent for over 40 years, and current routine usage in dermatology is not restricted to licensed indications. Advances in understanding the metabolic fate of azathioprine have led to significant changes in prescribing practice and toxicity monitoring by U.K. dermatologists. The current state of knowledge concerning the use of azathioprine in dermatology is summarized, with identification of strength of evidence. Clinical indications and contraindications for azathioprine usage in dermatology are identified. Evidence-based recommendations are made for routine safety monitoring of patients treated with azathioprine, including pretreatment assessment of red blood cell thiopurine methyltransferase activity.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15606506     DOI： 10.1111/j.1365-2133.2004.06323.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


  18 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase.

Authors:  M Konstantopoulou; A Belgi; K D Griffiths; J R C Seale; A W Macfarlane
Journal:  BMJ       Date:  2005-02-12

Review 3.  Atopic and non-atopic eczema.

Authors:  Sara Brown; Nick J Reynolds
Journal:  BMJ       Date:  2006-03-11

Review 4.  Azathioprine prescribing in neurology.

Authors:  P Goldsmith; G Lennox; N Bhalla
Journal:  J Neurol       Date:  2008-05-16       Impact factor: 4.849

5.  Indian Society of Gastroenterology consensus statements on Crohn's disease in India.

Authors:  Balakrishnan S Ramakrishna; Govind K Makharia; Vineet Ahuja; Uday C Ghoshal; Venkataraman Jayanthi; Benjamin Perakath; Philip Abraham; Deepak K Bhasin; Shobna J Bhatia; Gourdas Choudhuri; Sunil Dadhich; Devendra Desai; Bhaba Dev Goswami; Sanjeev K Issar; Ajay K Jain; Rakesh Kochhar; Goundappa Loganathan; Sri Prakash Misra; C Ganesh Pai; Sujoy Pal; Mathew Philip; Anna Pulimood; Amarender S Puri; Gautam Ray; Shivaram P Singh; Ajit Sood; Venkatraman Subramanian
Journal:  Indian J Gastroenterol       Date:  2015-03-14

Review 6.  Chronic non-infectious uveitis in the elderly: epidemiology, pathophysiology and management.

Authors:  Rajen Gupta; Philip I Murray
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

7.  Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.

Authors:  Mary V Relling; Matthias Schwab; Michelle Whirl-Carrillo; Guilherme Suarez-Kurtz; Ching-Hon Pui; Charles M Stein; Ann M Moyer; William E Evans; Teri E Klein; Federico Guillermo Antillon-Klussmann; Kelly E Caudle; Motohiro Kato; Allen E J Yeoh; Kjeld Schmiegelow; Jun J Yang
Journal:  Clin Pharmacol Ther       Date:  2019-01-20       Impact factor: 6.875

8.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 9.  Azathioprine for multiple sclerosis.

Authors:  I Casetta; G Iuliano; G Filippini
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 10.  Using systems approaches to address challenges for clinical implementation of pharmacogenomics.

Authors:  Jason H Karnes; Sara Van Driest; Erica A Bowton; Peter E Weeke; Jonathan D Mosley; Josh F Peterson; Joshua C Denny; Dan M Roden
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2013-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.